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SuMMAry – The aim of this retrospective study was to present the impact of successful optimal 
cytoreductive therapy on the overall prognosis of ovarian cancer treatment. Several factors were ana-
lyzed, including clinical (stage, age and parity), histopathologic/cytological (histologic type and grade 
of tumors, cytological findings of ascites or peritoneal washout), and therapeutic (surgery performed 
with the degree of cytoreduction, adjuvant chemotherapy and response to therapy). The study in-
cluded 126 patients treated during a 5-year period at the department of gynecology and Obstetrics, 
Osijek university hospital Centre in Osijek. Patient age ranged from 29 to 82, total 5-year survival 
was 55.5% and median survival was 76.2 months. Optimal cytoreduction (residual tumor <1 cm) was 
performed in 49.2% of patients. On data analysis, the life chart method, χ2-test and Cox regression 
analysis were used. The level of significance was set at p<0.05. Parity, histologic tumor grade, presence 
of malignant cells in ascites and peritoneal washout, as well as clinical stage yielded statistical signifi-
cance on univariate analysis. Cytoreductive ovarian cancer therapy turned out to be a significant prog-
nostic factor and on multivariate analysis proven to be an independent prognostic factor. Optimal 
cytoreduction, besides direct effect on survival, improved the quality of therapeutic response of the 
tumor to chemotherapy.
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Introduction
Ovarian cancer is the sixth most common cancer 
among women in Croatia, with 432 newly reported 
cases in 2004 (rate 18.8/100 000) and 240 reported 
deaths (12.2/100 000). Most often, ovarian cancer oc-
curs after menopause, especially among women after 
their sixties. in Croatia, the incidence and mortality 
rates caused by ovarian cancer are increasing1.
Malignant epithelial ovarian tumors characteristi-
cally spread by implanting tumor fragments along the 
abdominal peritoneum, i.e. by transcoelomic spread. 
This typically occurs along the serosa of the lower ab-
dominal cavity and small pelvis, in the subserous stro-
mal tissue and adipose omentum tissue, and along the 
diaphragmatic serosa and glisson liver capsule. Mul-
tiple implants may be separated fragments of the ovar-
ian cancer, but it is believed that they may also be an 
expression of the localized (in situ) proliferation of the 
peritoneum, under the influence of the same carcino-
genic agent that caused the development of epithelial 
ovarian cancer.
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Most authors today agree that the only prognostic 
factor effective in the treatment of ovarian cancer is 
surgical cytoreductive therapy. The exact stage of the 
condition can only be determined by a primary surgi-
cal approach, which also allows removal of as much 
tumor tissue as possible in order to create favorable 
conditions for further treatment with chemotherapy.
Complete reduction is achieved if there is no residu-
al tumor left. Optimal cytoreduction is, according to 
gynecologic Oncology group (gOg) studies 114 and 
172 started in 2001/20022,3, the reduction of tumor tis-
sue down to an individual size of less than one centime-
ter, which leads to a higher survival probability1.
There are three features regarding surgical cytore-
duction that should be taken into consideration. The 
first is physiological benefit; namely, as the spread of 
the disease along the abdominal cavity causes disrup-
tion of gastrointestinal functions, the catabolic effect 
of the tumor is reduced along with reduction of the 
tumor mass. Secondly, sensitivity to cytostatic therapy 
is increased by improving vascularization of the resid-
ual tumor mass. Thirdly, the immune gain is achieved 
with removal of large tumor masses, which results in 
the increase of the natural killer (nK) cell and cyto-
toxic t lymphocyte activity in patient serum4.
There are three designated levels of cytoreductive 
surgery in ovarian cancer therapy. The standard ap-
proach includes total abdominal hysterectomy and bi-
lateral salpingo-oopherectomy (tAh-BSO), supra-
colic omentectomy, appendectomy and paraaortic 
lymphadenectomy. The radical approach includes the 
standard approach along with the en bloc resection of 
the rectosigmoid colon and coloanal anastomosis 
(hudson procedure). The supraradical approach in-
cludes the previous two approaches along with other 
digestive resections, splenectomy, and extensive abla-
tion of the peritoneum including diaphragm strip-
ping4,5.
radical and supraradical surgery is validated in 
cases where complete or optimal cytoreduction is ex-
pected. in these cases, a five-year survival up to 50% 
can be expected. in patients with unresectable tumors, 
chemosurgical cytoreduction (neoadjuvant chemo-
therapy followed by surgical cytoreduction) is a better 
option.
The resectability criteria are age, patient condition, 
presence of metastasis outside the abdomen, massive 
peritoneal invasion, massive implants of coronary liga-
ments of the liver, metastases in suprarenal lymph 
nodes, and massive invasion of the intestinal mesen-
tery1. recently, chemotherapy of ovarian cancer is car-
ried out with taxan compounds (with paclitaxel as the 
first choice). if paclitaxel is used alone, it leads to re-
mission in 36% of previously treated patients. The 
combination of paclitaxel and cisplatin is renowned as 
the most efficient combination in ovarian cancer treat-
ment, as it achieves remission in almost 70% of pa-
tients6.
gynecologic Oncology group studies have shown 
that intravenous administration of chemotherapeutics 
(paclitaxel with cisplatin) in combination with intra-
peritoneal administration (also paclitaxel with cisplat-
in) in stage iii patients with optimal cytoreduction 
(residual tumor <1 cm) leads to prolonging of the dis-
ease-free intervals by 5.5 months, and to improvement 
of total survival by 15.9 months7. The outcome of ther-
apy is generally affected by clinical stage of the disease, 
therefore, the five-year survival is 80%-100% in the 
first and second stages, 20%-40% in the third stage, 
and only 5%-10% in the fourth stage8.
Patients and Methods
The study included female patients treated for 
ovarian cancer in the period between January 1, 2000 
and december 31, 2004 at the department of gyne-
cology and Obstetrics, Osijek university hospital 
Centre in Osijek, Croatia. data collected from patient 
medical history, operative protocols, histopathologic 
and cytological findings, and patient oncologic records 
were retrospectively analyzed.
The study included 126 patients aged 29 to 85. The 
following clinical prognostic factors were analyzed: 
clinical stage, age and parity. The histopathologic fac-
tors analyzed were histologic type and grade, cytologi-
cal findings of ascites, and peritoneal washout. Finally, 
the therapeutic factors analyzed were surgical treat-
ment applied with the level of cytoreduction, adjuvant 
chemotherapy, and response to chemotherapy.
Clinical stage was divided into four groups accord-
ing to the 1998 FigO criteria9. histologic grade of 
the tumor was divided into four stages according to 
the American Joint Commission on Cancer (AJCC)10. 
The centrifugal residue of the ascites and peritoneal 
washout was stained by Mgg technique and tested 
according to standard cytological criteria for malig-
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nant cells. When the results proved to be disputable, 
special staining was used to test immunologic factors.
Surgical treatment with the level of cytoreduction 
was determined according to the criteria used in the 
2011/2002 gOg studies2,3. Adjuvant chemotherapy 
was administered according to standards of ovarian 
cancer treatment. response to chemotherapy was de-
scribed as total remission, partial remission, or pro-
gression. remission of the disease was proven by tu-
mor markers (CA-125), abdominal ultrasound, tv 
3d ultrasound, x-ray of the lungs, and computed to-
mography of the abdomen. All of these parameters 
were within physiological limits and used to determine 
total remission. Partial remission was considered in 
cases where it could be proven by these parameters, but 
on a smaller scale than before. if the disease was prov-
en to be of a greater scale than before (despite treat-
ment), then it was considered disease progression.
Analysis of survival was based on patient observa-
tion data collected from the point of diagnosis to ei-
ther the point of death from the original disease (ad-
verse outcome), or to the point of termination of ob-
servation (favorable outcome or census). The probabil-
ity of survival was calculated according to the life chart 
method and presented visually using Kaplan-Meier 
curves. Statistical indicators of survival analysis are 
based on a log-normal data distribution. The simulta-
neous effect of all indicators on survival prognosis 
(clinical, histopathologic and therapeutic) was ana-
lyzed using the method of multivariate regression with 
incomplete data (Cox regression analysis). The χ2-test 
was used to determine correlation between the level of 
cytoreduction and chemotherapy. reaching conclu-
sions on statistical hypotheses was done with a signifi-
cance level of p<0.05 for all the tests applied. The SPSS 
for Windows software (version 17.0 SAS institute 
inc., Cary, nC, SAd) was used for statistical analysis.
Results
during the study period, 64 (50.7%) subjects died. 
The median survival was 76.2 months and total five-
year survival was 55.5%. The study included patients 
aged between 29 and 82. Figure 1 shows distribution 
of patients according to age. it is notable that the larg-
est number of patients were aged 65-69 (15.8%). After 
dividing patients into two groups according to age 
(<50 and >50), younger patients were found to have 
better survival, but the difference was not statistically 
significant. Cox regression analysis showed that age 
was not an independent prognostic factor (p=0.309).
According to parity, patients were divided into 
groups with 0 (nulliparous), 1, 2, and 3 or more chil-
dren. Figure 2 shows distribution of patients according 
to parity. it is noticeable that the majority of patients 
had two children (39.7%). Patients with 0, 1 or 2 chil-
dren had better survival than those with 3 or more 
children. The difference was statistically significant 
only on univariate analysis (p<0.0001).
Patient distribution according to clinical stages 
showed that almost half of ovarian cancers were de-
tected in the advanced third stage of the disease (Fig. 
3). Patient survival according to FigO staging was 
presented using Kaplan-Meier curves. The five-year 
survival in the first stage of the disease was best, 
amounting to 85%, but survival dropped in higher 
stages and was 60% in second stage, and only 25% in 
Fig. 1. Disease distribution according to patient age.
Fig. 2. Patient distribution according to parity.
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third and fourth stages (Fig. 4). Statistical analysis 
yielded no statistically significant difference between 
the first and second clinical stages, while the difference 
between the first and third, and first and fourth stages 
indicated a statistically significantly better five-year 
survival in the first stage (p<0.00019).
The most frequent histologic type of tumor was se-
rous carcinoma (58%), followed by mucinous (12.7%), 
undifferentiated (8.6%), endometrioid (7.1%), and 
clear cell carcinoma (4.8%), granulosa cell tumor 
(3.2%) and immature teratoma (1.5%), while other 
histologic types of tumors were less frequent (<1%). 
granulosa cell tumors had the best prognosis and 
100% five-year survival, whereas undifferentiated tu-
mors had the worst prognosis with only 10% five-year 
survival (Fig. 5).
Figure 6 shows that ovarian tumors were most of-
ten (40%) poorly differentiated (g3), whereas well- 
and moderately differentiated tumors were less fre-
quent and made up only 35% of all tumors. it should 
be noted that the histologic grade in pathologic find-
ings was not determined in one-quarter of all patients. 
The survival according to histologic grade was present-
ed with Kaplan-Meier curves (Fig. 7). The five-year 
survival of patients with well-differentiated tumors 
(g1) was 94.4%, for moderately differentiated tumors 
it was 69.2%, and for poorly differentiated tumors it 
was only 23.5%. The difference in survival between 
well- and moderately differentiated tumors, and be-
tween well- and poorly differentiated tumors was sta-
tistically significant (p<0.0001). histologic grade is a 
significant prognostic factor in univariate analysis, but 
was proven not to be an independent prognostic factor 
in multivariate analysis.
Ascites was present in 38.1% of patients; 89.6% of 
ascites were cytologically positive for malignant cells. 
Peritoneal washout was carried out in 53.9% of cases 
Fig. 3. Patient distribution according to FIGO stage.
Fig. 4. Kaplan-Meier curves for overall survival 
according to FIGO stage.
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Fig. 5. Five-year survival rate according to histologic type of tumor.
Fig. 6. Patient distribution according to histologic grade of tumor.
Fig. 7. Kaplan-Meier curves for overall survival 
according to histologic grade.
where there was no ascites present, and was positive in 
35.3%. Peritoneal washout was not carried out in 7.9% 
of patients (Fig. 8). univariate analysis yielded a statis-
tically significantly (p<0.001) worse survival in pa-
tients with cytologically positive findings of the asci-
tes. There was a statistically significant difference in 
survival between patients whose peritoneal washout 
was positive and those whose washing was negative 
(p<0.003). independent prognostic significance was 
not proven by multivariate analysis.
Optimal cytoreduction was carried out in almost 
half (49.2%) of the primarily surgically treated patients 
according to the 2001/2002 gOg guidelines with re-
sidual tumor of <1 cm. Suboptimal cytoreduction with 
residual tumor of <2 cm was carried out in 40.5% and 
explorative laparotomy in 10.3% of cases. There was a 
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significant difference in survival between patients with 
optimal and suboptimal cytoreduction (p=0.0001) 
(Fig. 9). univariate analysis indicated optimal cytore-
duction to be a statistically significant prognostic fac-
tor for survival. Multivariate analysis showed that 
among all other prognostic factors tested, only optimal 
cytoreduction was a statistically significant and inde-
pendent prognostic factor for survival in ovarian can-
cer patients (p=0.001).
Chemotherapy was administered to 73% of pa-
tients. Around two-thirds (66.3%) were treated with a 
combination of paclitaxel and carboplatin, and 33.6% 
with another kind of chemotherapy. Analysis revealed 
that survival depended on the type of chemotherapy, as 
survival in patients treated with paclitaxel amounted 
to 55%, while in those using other chemotherapeutics 
it was 40%. however, this difference was not statisti-
cally significant. Considering type of chemotherapy, 
79.4% of patients received first-line, 15.2% received 
second-line, and 5.4% received third-line chemothera-
py. Both univariate and multivariate analyses showed 
the number of lines and cycles of chemotherapy to be 
statistically nonsignificant and were not independent 
prognostic factors. it was analyzed how the level of cy-
toreduction influenced chemotherapy response. data 
showed that there was a statistically significant differ-
ence between patients having undergone optimal cy-
toreduction and those having undergone inadequate 
cytoreductive surgery (p=0.0001).
As shown in Figure 10, total remission was achieved 
by chemotherapy and optimal cytoreduction in 86.9% 
of cases, but only 25.5% of patients when utilizing 
suboptimal cytoreduction. The patients having under-
gone only suboptimal cytoreduction mostly had partial 
remission (43.1%). Progression of the disease occurred 
in 4.9% of patients undergoing optimal cytoreduction, 
and in astonishing 31.4% when undergoing subopti-
mal cytoreduction. A few of the prognostic factors 
tested are presented in table 1, along with their statis-
tical significance in univariate and multivariate analy-
sis. As shown in this table, parity, histologic grade, 
presence of malignant cells in the ascites and perito-
neal washout, and clinical stage had a statistically sig-
nificant role in survival, whereas optimal cytoreduction 
was the only independent prognostic factor.
Fig.8. Presence of malignant cells in ascites or peritoneal 
washout.
Fig.9. Kaplan-Meier curves for overall survival 
according to optimal cytoreduction.
Fig.10. Overview of responses to chemotherapy depending 
on the level of cytoreduction.
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Discussion
According to the 2001/2002 gOg guidelines, the 
basic goal of all cytoreductive procedures is complete 
removal of the tumor (total cytoreduction), or reduc-
tion of the tumor down to the residual size of <1 cm 
(optimal cytoreduction)1.
The peak incidence of ovarian cancer in the study 
group was between age 65 and 69, which corresponds 
to literature data11. in this case, however, age was not 
shown to be a statistically significant variable for sur-
vival, although the group of patients above 50 years of 
age had worse survival than the group of younger pa-
Table 1. Prognostic value of selected prognostic factors
Prognostic factor Subjects Five-year survival  rate (%)
p value
number (n) % univariate Multivariate
Parity
0.028 nS*
0 18 14.4 61.1
1 30 24.0 56.7
2 52 41.6 53.8
3 and more 26 20.4 31.2
grade
0.000 nS
g1 18 14.4 94.4
g2 26 20.8 69.2
g3 52 40.8 23.5
unknown 30 24.0 53.3
response to chemotherapy
0.00 nS
unknown 30 24.6 27.4
Progression 15 12.3 0.0
Partial remission 30 24.6 11.3
total remission 47 38.5 61.3
Ascites
0.00 nSnegative 83 65.3 83.9
Positive 43 34.7 16.1
Paclitaxel/carboplatin
nS nSno 43 33.7 54.0
yes 83 66.3 46.0
number of therapy lines
nS nS
0 34 27.2 34.9
1 75 59.2 57.1
2 14 11.2 6.3
3 2 1.6 0.0
6 1 0.8 1.6
Peritoneal washout 
cytology
0.003 nSnegative 49 64.7 79.6
Positive 23 35.3 20.4
Optimal cytoreduction
0.00 0.00no 68 50.8 23.8
yes 57 49.2 76.2
nS = nonsignificant
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tients. According to the studies by Makar et al.12 and 
Chi et al.13, age is an independent prognostic variable 
when it comes to advanced ovarian cancer.
Most of the patients in this study had two children, 
and quite unexpectedly, the rate of nulliparous patients 
was 14.4%. Patients with three or more children had a 
statistically significantly worse five-year survival. Pari-
ty was not shown to be an independent prognostic fac-
tor in multivariate analysis. The FigO stage was, as 
expected, shown to be a statistically significant prog-
nostic factor, but not independent, as stated by other 
authors14. Almost half of the carcinomas were detected 
in the advanced third FigO stage, where the five-year 
survival was only 25%. it was in this stage where most 
of the suboptimal cytoreduction and explorative lapa-
rotomy procedures took place, suggesting that the size 
of residual tumor rather than the stage of tumor ex-
pansion plays a key role in prognosis.
The most common histopathologic tumor type was 
serous cancer (58%) with five-year survival of 41.9%. 
Other authors report on the histopathologic tumor 
type to be a statistically significant prognostic factor, 
emphasizing that serous and endometrioid types have 
better prognosis than mucinous and clear cell carci-
noma12.
Our results showed that poorly differentiated tu-
mors (g3) were most frequently identified in histo-
pathologic findings. univariate analysis showed that 
grade was statistically significant (p=0.0001), but was 
not proven to be an independent prognostic factor by 
multivariate analysis. retrospective research by other 
authors has shown the same results13.
Patients with positive ascites had a statistically sig-
nificantly worse survival than those with negative asci-
tes (p<0.001). Similar results were recorded in patients 
with positive peritoneal washout. Our study showed 
that positive ascites was not an independent prognos-
tic factor, unlike the results reported by other authors13. 
Considering that cytological findings of malignant 
cells in the ascites have been incorporated in the FigO 
classification, it was logical to assume that neither of 
the two prognostic factors would be statistically sig-
nificant in multivariate analysis.
The success of surgical treatment depended on the 
level of cytoreduction. half of the patients had under-
gone optimal cytoreduction, which was shown to be a 
significant prognostic factor in univariate analysis 
(p<0.0001), while multivariate analysis indicated that 
optimal cytoreduction was an independent prognostic 
factor for survival of ovarian cancer patients (p<0.01). 
Such data have also been reported elsewhere, but 
mostly for advanced ovarian cancers. A 2002 meta-
analysis by Bristow et al.7 on 6885 stage iii and iv 
epithelial ovarian cancer patients evaluated different 
prognostic factors for survival. Positive correlation was 
observed between maximal surgical cytoreduction and 
survival median, even in multivariate analysis. Every 
10% increase of maximal cytoreduction was correlated 
to 5.5% increase in the survival median. Most of the 
studies included in this meta-analysis were defined by 
maximal cytoreduction of 1-2 cm of residual tumor. 
Several reports state that the goal of primary cytore-
ductive surgery of epithelial ovarian cancer should be a 
state with no residual tumor15-18. in our patients, me-
dian survival was 76.2 months regardless of the level of 
cytoreduction. Other studies report on median sur-
vival of 99 months18 and 106 months16, but only for 
patients with no residual disease. There is also report 
on only 23.8% survival in patients having undergone 
suboptimal cytoreductive treatment15.
in our study, 73% of patients received chemothera-
py after surgical treatment, 63.3% of them paclitaxel/
carboplatin as first-line chemotherapy. univariate 
analysis showed that survival was better in patients 
having received the combination of paclitaxel and car-
boplatin as first-line chemotherapy than in those hav-
ing received other chemotherapeutics. This difference, 
however, was not statistically significant. This result 
corresponds to those reported by other authors7. The 
number of chemotherapy lines was shown to be statis-
tically significant when linked to optimal surgery, but 
was not significant in relation to the operative proce-
dure itself. This means that the patients having under-
gone optimal cytoreduction should have received a 
smaller number of chemotherapy lines and cycles. Af-
ter analyzing the number of lines and cycles of each 
type of chemotherapy, our data revealed that neither 
the number of lines nor the number of cycles was sta-
tistically significant. The number of lines and cycles 
was determined by the quality of therapeutic response 
rather than by one of the variables tested.
The response to chemotherapy was, depending on 
the level of cytoreduction, of notable statistical signifi-
cance. According to Eisenhauer et al.15, patients having 
started receiving chemotherapy after optimal cytore-
ductive surgery had a statistically significantly better 
survival. Our analysis also showed better survival, and 
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this difference was statistically significant. This points 
to a conclusion that patients having undergone opti-
mal cytoreduction experienced total remission after 
chemotherapy more often. total remission of the dis-
ease was observed in 86.9% of patients who had un-
dergone chemotherapy after optimal cytoreduction, 
but in only 25.5% of patients having undergone the 
same chemotherapy after suboptimal cytoreduction. 
The response to chemotherapy was not shown to be an 
independent prognostic factor in multivariate analysis.
to conclude, we can say that optimal cytoreductive 
treatment of ovarian cancer is an independent prog-
nostic factor for survival, and it also improves patient 
response to chemotherapy.
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Sažetak
PrOgnOStiČKO ZnAČEnJE CitOrEduKCiJE KOd rAKA JAJniKA  
– iSKuStvO iZ iStOČnE hrvAtSKE
Z. Topolovec, T. Horvat, D. Vidosavljević, S. Šijanović, A. Müller-Vranješ, M. Ugljarević, D. Milojković i S. Topolovec
Cilj ove retrospektivne studije bio je prikazati utjecaj optimalne citoreduktivne terapije na ukupnu prognozu liječenja 
raka jajnika. Analizirano je nekoliko čimbenika uključujući kliničke (stupanj, dob i paritet), histopatološke/citološke (histo-
loški tip i stupanj tumora, citološki nalaz ascitesa ili peritonealnog ispiranja) i terapijske značajke (operativni zahvat sa stup-
njem citoredukcije, adjuvantne kemoterapije i odgovora na terapiju). u istraživanju je sudjelovalo 126 bolesnica liječenih 
 tijekom petogodišnjeg razdoblja na Klinici za ginekologiju i opstetriciju Kliničkog bolničkog centra u Osijeku. dob bolesni-
ca bila je u rasponu od 29 do 82 godine, ukupno petogodišnje preživljavanje bilo je 55,5%, a medijan preživljenja 76,2 mje-
seca. Optimalna citoredukcija (rezidualni tumor <1 cm) provedena je u 49,2% bolesnica. na temelju analize podataka kori-
štena je metoda dijagrama preživljenja, χ2-test i Coxova regresijska analiza. razina značajnosti je postavljena na p<0,05. 
 Paritet, histološki stupanj tumora, prisutnost malignih stanica u ascitesu i peritonealnom ispiranju, kao i klinički stadij su se 
pokazali statistički značajni pri univarijatnoj analizi. Citoreduktivna terapija raka jajnika pokazala se značajnim prognostič-
kim čimbenikom i prikazana je u multivarijatnoj analizi kao neovisni prognostički čimbenik. Optimalna citoredukcija, osim 
izravnog učinka na preživljavanje, poboljšala je i kvalitetu terapijskog odgovora tumora na kemoterapiju.
Ključne riječi: Ovarijski tumori; Citoredukcijski kirurški postupci; Prognoza; Retrospektivne studije; Kemoterapija, adju vantna; 
Hrvatska
